semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Influenza A male or female 18 years of age or greater at the time of the first vaccination Written informed consent obtained from the subject Among 18 to 49 year old subjects, good general health as established by medical history and clinical examination before entering into the study Among subjects > 49 years of age, stable health status within 1 month prior to enrollment Access to a consistent means of telephone contact Comprehension of the study requirements, ability to comprehend and comply with procedures for collection of short and long-term safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits  Evidence of substance abuse or of neurological or psychiatric diagnoses which, even if clinically stable, are deemed by the investigator to render the potential subjectunable/unlikely to provide accurate safety reports Diagnosed with cancer, or treatment for cancer, within 3 years An oral temperature ≥37.8º C, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus infection Receipt of systemic glucocorticoids within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin Administration of any vaccines within 30 days before study enrollment Previous administration of any H5N1 vaccine Use of any investigational or non-registered product or planned participation in another investigational study within 30 days prior to study enrollment, or during the 364 days following the first test article dose. Use of any investigational or non-registered product with immunosuppressive properties is exclusionary at any time during the trial Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  Healthy Age 18-49 years Available for clinic visits at Tufts-New England Medical Center Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) obtained Ability of participant to understand and comply with the requirements of the protocol  History of any medical conditions for which the CDC states should not be vaccinated with LAIV (asthma, reactive airways disease, other chronic disorders of the pulmonary or cardiovascular systems; metabolic diseases such as diabetes, renal dysfunction, and hemoglobinopathies; or persons with known or suspected immunodeficiency diseases) Self-reported vaccination with the influenza vaccine for the current influenza season (2007-8); vaccination with any vaccine within the one month period prior to study enrollment or intent to receive any other vaccine during the study period; hypersensitivity to any influenza vaccine components including thimersol or egg or Guillain-Barre syndrome Self-reported treatment with immunomodulator/immunosuppressor drugs (interleukins, corticosteriods (oral or inhaled)), G(M)-CSF in 4 weeks before enrollment or self-reported history of IL-2 administration within 5 years; use of theophylline preparations or warfarin because of the theoretical possibilities of enhanced drug effects and toxicities following influenza vaccination; medication use that might affect the immune response to a vaccine or effects of LGG (no antibiotics during the previous 4 weeks) Current alcohol, substance abuse, or systemic/psychiatric illness that potentially could interfere with compliance and ability to make study visits Health care or day care workers or close contacts with immunosuppressed persons because of the theoretical risk that LAIV could be transmitted to the immunosuppressed person and cause disease, per CDC recommendations Use of LGG or other probiotics in 4 weeks before enrollment. Yogurt consumption is not an  but subjects will be asked to avoid consumption of other lactobacilli and probiotic organisms during the study period Abnormalities upon physical examination Acute febrile illness on day of intended immunization immunization deferred until illness resolved
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ocular Melanoma Patients must have uveal melanoma for which enucleation is indicated, usually lesions greater than 8 mm in diameter and greater than 2 mm in thickness Patients should have no evidence of metastatic disease as determined by history, physical examination, and appropriate liver injury enzymes Patients should have received no prior interferon Age >18 years. Because of limited data on the use of pegylated interferon in patients <18 years of age and uncertainties about possible differences in NK response, children are excluded from this study. Since ocular melanoma is rare in children this is not expected to be an issue Life expectancy of greater than 3 months ECOG performance status of 0 (Karnofsky 60% or better; see Appendix II) Patients must have normal organ and marrow function as defined below Hgb >/= 12.5 g/dl or hematocrit >/= 38% Leukocytes >3,000/mcL  Patients who have had agents known to be immunosuppressive (e.g, glucocorticoids) within the 4 weeks prior to planned receipt of study drug Patients receiving any other investigational agents Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Pregnant women are excluded from this study because interferon alpha has the potential for teratogenic effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with interferon, breastfeeding should be discontinued if the mother is treated with this agent HIV-positive patients are ineligible because of the known immunosuppression associated with this disease Patients with history of other malignancies are eligible provided that they are clinically free of metastases at the time of the study Patients who have donated blood in the 56 days prior to the 500cc blood draw in this study are not eligible
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 49.0-67.0,  Menopause Osteopenia Good general health Have not had a menstrual period in the preceding year Had not undergone surgically induced menopause Had a follicle-stimulating hormone level > 50 IU/liter and a serum 17 beta-estradiol level ≤ 100 pmol/liter Established osteopenia (-1<T-score<-2.5 SD)  Clinical or laboratory evidence of confounding systemic diseases, such as cardiovascular, hepatic, or renal disorders Coagulopathy, use of oral or transdermal estrogen, progestin, androgen or other steroids Biphosphonates, cholesterol-lowering therapy or cardiovascular medications in the preceding six months Smoking habit of more than two cigarettes per day Previous treatment with any drug that could affect the skeleton in the preceding year A family history of estrogen-dependent cancer BMD at femoral neck > 0.795 g/cm2; this BMD value corresponds to a T score of -1 standard deviation
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 35.0-90.0,  Breast Neoplasms Ultrasonography be at least 35 years old, unless she has a strong pre-menstrual family history of breast cancer have had no screening mammogram in the past 10 months agree to have a screening mammogram that will not be reviewed until after a SonoCiné is performed agree to have a screening mammogram in approximately one year agree to answer follow up question in approximately one year meet the usual for breast screening (be asymptomatic of focal breast disease) have no history of breast cancer for at least one year agree to have both mammogram and SonoCiné if a physical finding or mammographic finding occurs within one year that requires biopsy  greater than 7 cm compressed breast thickness at mammography
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  To Determine the Bioavailability of Tranylcypromine Subjects will be normal, healthy adult men and women who volunteer to participate Is the individual healthy, nonsmoking, normal adult man or woman who volunteers to participate? Is s/he at least 18 years of age? Is his/her BMI between 19 and 30, exclusive? Is she willing to avoid pregnancy by abstaining from sexual intercourse, or by the use of barrier methods. (diaphragm, condom, foams/jellies, sponge), and IUD, or has she has been surgically sterile or post menopausal at least six months prior to entering into the study? Is s/he considered reliable and capable of understanding his/her responsibility and role in the study? Has/s/he provided written informed consent? A no answer to any of the above questions indicates taht the individual is ineligible for enrollment  Does the individual have a history of allergy or hypersensitivity to tranylcypromine? Does/ s/he have clinically significant laboratory abnormalities that would interface with the conduct or interpretation of the study or jeopardize his/her safety? Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interface with the conduct or interpretation of the study or jeopardize his/her safety? Is she nursing? Does s/he have serious psychological illness? Does s/he have significant history ( within the past year) or clinical evidence of alcohol or drug abuse? Does s/he have a positive urine drug screen or saliva alcohol screen, or a positive HIV-1 , or hepatitis B or C screen, or a positive pregnancy test?-Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the alst blood sample has been taken? Is s/he unable to refrain from the ingestion of smoked meat, cheese (except cream cheese and cottage cheese), wine and beer during periods beginning 48 hours prior to study initiation and ending seven days after the last blood sample has been taken in study period two? Has s/he used any prescription drug during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation? Is s/he unable to refrain from the use of all concomitant medications during the study?
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Conjunctivitis, Allergic At least 18 years of age & either sex, any race Willing and able to follow all instructions and attend all study visits Positive history of ocular allergies Reproducible positive ocular allergic reaction induced by conjunctival allergen challenge  Have planned surgery during trial period Female currently pregnant, planning a pregnancy, or lactating Use of disallowed medications
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Healthy Normal healthy volunteer Age must be between 18 and 50 years of age  Have a job in which you handle food Are a health care worker with direct patient contact Work in a child care, elderly care center or if you live with young children or anyone who has a weak immune system Are not willing or able to wash your hands every time after you go to the bathroom, or before and after you prepare or handle food throughout the whole study Are anemic Are not willing to give us permission to store and use your data and samples
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hodgkin's Disease Non-Hodgkin's Lymphoma Histologically confirmed relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's Disease (WHO criteria), for which they are unwilling or unable to undergo an autologous stem cell transplant 2. Must have received first line chemotherapy. No upper limit to number of prior therapies 3. Evaluable Disease 4. Age >18 years 5. Eastern Cooperative Oncology Group (ECOG) performance status <2 6. Life expectancy of greater than 3 months 7. Patients must have adequate organ and marrow function 8. Adequate Contraception 9. Ability to understand and the willingness to sign a written informed consent document  Prior Therapy Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone during the 7 days prior to the start of the study drugs No monoclonal antibody within 3 months unless evidence of progression 2. Patients may not be receiving any other investigational agents 3. Patients with known central nervous system metastases, including lymphomatous meningitis 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat, niacinamide or etoposide 5. Uncontrolled intercurrent illness 6. Pregnant women 7. Nursing women 8. Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 3 years 9. Patient is known to be Human Immunodeficiency Virus (HIV)-positive 10. Active Hepatitis A, Hepatitis B, or Hepatitis C infection 11. Patient has a history of surgery that would interfere with the administration or absorption of the oral study drugs
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Melanoma Male or female patient with histologically proven, measurable metastatic cutaneous melanoma, and with documented progressive disease within the 12 weeks before the first administration of study treatment Written informed consent has been obtained from the patient before the performance of any protocol-specific procedure Patient is >= 18 years of age at the time of signature of the informed consent The patient's tumor shows expression of MAGE-A3 gene ECOG performance status of 0 or 1 The patient has normal organ functions If the patient is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during all study treatment period and for 2 months after completion of the injection series In the view of the investigator, the patient can and will comply with the requirements of the protocol  The patient has at any time received systemic (bio-)chemotherapy (except for isolated limb perfusion, as long as this was performed at least 4 weeks before first study treatment administration) The patient is scheduled to receive any anti-cancer specific treatment, including radiotherapy, immunotherapy, chemotherapy and immunomodulating agents The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents The patient received any cancer immunotherapeutic containing a MAGE-A3 antigen or any cancer immunotherapeutic for his/her metastatic disease The patient has received any investigational or non-registered drug or vaccine other than the study medication within the 30 days preceding the first ASCI injection or it is planned that (s)he will receive such a drug during the study period The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded The patient has a family history of congenital or hereditary immunodeficiency The patient is known to be positive for the Human Immunodeficiency Virus (HIV)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vaccination Receiving yellow fever vaccination English speaker Aged over 18  No phone for follow-up
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 4.0-999.0,  Food Allergies Chronic, reproducible symptoms following meals. 2. Multiple food allergies where dietary avoidance is nearly impossible. 3. Patients age 4 and older. 4. Testing to verify food allergies is positive  History of anaphylaxis, angioedema, asthma, or life-endangering reactions to certain food products. 2. Children under the age of 4. 3. Previous attempts to treat food allergy (subcutaneous injections). 4. General medical condition that precludes elective therapy (including pregnancy). 5. Inability to follow food allergy SLIT regimen. 6. Autoimmune Disease. 7. Chronic use of steroids
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Dyslipidemia Subjects must have successfully completed the 4-week treatment period of study AT302-U-06-003  Females who are pregnant or lactating, and females of child bearing potential who are not using an effective method of contraception Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol Subjects who cannot follow the prescription and OTC medication restrictions defined in the protocol Flu-shots not permitted during the study, including the follow-up period
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pelvic Inflammatory Disease women admitted to Emergency with pelvic-inflammatory disease or tubo-ovarian abscess from the year range: 1995-2000